

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gantier *et al.*
Serial No.: 10/658,834
Filed : September 08, 2003
Cust. No.: 24961
Conf. No.: 7681
For: **RATIONAL EVOLUTION OF
CYTOKINES FOR HIGHER
STABILITY, THE CYTOKINES
AND ENCODING NUCLEIC
ACID MOLECULES**
Art Unit: 1644
Examiner: Unassigned

TRANSMITTAL LETTER

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith via hand delivery are an Information Disclosure Statement, Form PTO-1449 (7 pages), and cited references for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-identified application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

(X) The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By: 
Stephanie L. Seidman
Registration No. 33,779

Dated: January 08, 2004
Attorney Docket No. 37851-0922
Address all correspondence to:
Stephanie L. Seidman, Esq.
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gantier *et al.*
Serial No.: 10/658,834
Filed : September 08, 2003
Cust. No.: 24961
Conf. No.: 7681
For: **RATIONAL EVOLUTION OF
CYTOKINES FOR HIGHER
STABILITY, THE CYTOKINES
AND ENCODING NUCLEIC
ACID MOLECULES**
Art Unit: 1644
Examiner: Unassigned

TRANSMITTAL LETTER

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith via hand delivery are an Information Disclosure Statement, Form PTO-1449 (7 pages), and cited references for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-identified application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

(X)

The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman
Registration No. 33,779

Dated: January 08, 2004
Attorney Docket No. 37851-0922
Address all correspondence to:
Stephanie L. Seidman, Esq.
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gantier *et al.*
Serial No.: 10/658,834
Filed: September 08, 2003
Cust. No.: 24961
Conf. No.: 7681
For: **RATIONAL EVOLUTION OF
CYTOKINES FOR HIGHER
STABILITY, THE CYTOKINES
AND ENCODING NUCLEIC ACID
MOLECULES**
Art Unit: 1644
Examiner: Unassigned

**INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE
WITH 37 C.F.R. §§ 1.97-1.98**

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits of the above-captioned application. Thus, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (7 pages) and copies of the cited documents are provided herewith in connection with the above-captioned application.

The documents listed on Form PTO-1449 and supplied herewith are all in the English language with the exception of items O and P. French patent

U.S.S.N. 10/658,834
Gantier *et al.*
Information Disclosure Statement

numbers FR 2802645 (item O) and FR 2808804 (item P), which are in the French language, are supplied with English language equivalents (items B and K, and items D and L, respectively) describing the subject matter. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following U.S. and International applications, which are commonly owned and/or have one or more inventors in common:

<u>U.S.S.N.</u>	<u>Filing Date</u>	<u>Publ'n. No.</u>	<u>Publ'n. Date</u>	<u>Docket No.</u>
10/022,249	12/17/01	2003-0134351	07/17/03	911
10/022,390	12/17/01	2003-0129203	07/10/03	912
10/375,192	02/24/03	2003-0224404	12/04/03	918
60/457,135	03/21/03			P922B
10/658,834	09/08/03			922
60/457,063	03/21/03			P923B
10/658,355	09/08/03			923

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

U.S.S.N. 10/658,834
Gantier *et al.*
Information Disclosure Statement

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,
HELLER EHRMAN WHITE & MCAULIFFE LLP

By: 
Stephanie L. Seidman
Registration No. 33,779

Dated: January 08, 2004
Attorney Docket No. 37851-0922
Address all correspondence to:
Stephanie L. Seidman
HELLER EHRMAN WHITE & MCAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@HEWM.com

FORM PTO-1449

ATTY. DOCKET NO.
37851-922SERIAL NO.
10/658,834CONFIRM NO.
7681APPLICANT
GANTIER et al.CUSTOMER NO.
24961FILING DATE
September 8, 2003GROUP
1644

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	0	1	2	9	2	0	3	07/10/03	Vega et al.	424	233.1	12/17/01
	B	0	1	2	9	5	8	4	07/10/03	Vega	435	5	12/13/00
	C	0	1	3	4	3	5	1	07/17/03	Vega et al.	435	69.1	12/17/01
	D	0	1	7	5	6	9	4	09/18/03	Vega	435	5	05/04/01
	E	3	2	2	4	4	0	4	12/04/03	Vega et al.	435	6	02/24/03
	F	4	0	4	4	1	2	6	08/23/77	Cook et al.	424	243	07/09/76
	G	4	3	6	4	9	2	3	12/21/82	Cook et al.	424	46	04/30/81
	H	4	4	1	4	2	0	9	11/08/83	Cook et al.	424	243	06/13/77
	I	4	5	2	2	8	1	1	06/11/85	Eppstein et al.	514	2	07/08/82

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	J	0	1	3	2	7	1	1	A2 05/10/01	PCT				
	K	0	1	4	4	8	0	9	A2 06/21/01	PCT				
	L	0	1	8	6	2	9	1	A1 11/15/01	PCT				
	M	03	0	2	3	0	3	2	A2 03/20/03	PCT				
	N	03	0	1	8	8	2	0	A2 03/06/03	PCT				
	O	2	8	0	2	6	4	5	A1 06/22/01	FR				X +


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449

ATTY. DOCKET NO.
37851-922SERIAL NO.
10/658,834CONFIRM NO.
7681
**U.S. DEPARTMENT OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT**
APPLICANT
GANTIER et al.CUSTOMER NO.
24961FILING DATE
September 8, 2003GROUP
1644

If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	P	2	8	0	8	8	0	4	A1 11/16/01	FR				X+

X+ = An English Language Equivalent is provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Q	Bellido <i>et al.</i> , "The phospholipid and fatty acid composition of skeletal muscle cells during culture in the presence of vitamin D-3 metabolites," <i>Biochim Biophys Acta</i> , <u>922(2)</u> :162-169 (1987)
R	Biron <i>et al.</i> , "Natural Killer Cells In Antiviral Defenses: Function and Regulation by Innate Cytokines," <i>Annu. Rev. Immunol.</i> , <u>17</u> :189-220 (1999)
S	Boger <i>et al.</i> , "Surface Probability Profiles. A Heuristic Approach to the Selection of Synthetic Peptide Antigens," <i>Reports of the Sixth International Congress in Immunology</i> , p. 250 (1986)
T	Briand <i>et al.</i> , "Impact of the lysine-188 and aspartic acid-189 inversion on activity of trypsin," <i>FEBS Lett.</i> , <u>442(1)</u> :43-47 (1999)
U	Dayhoff <i>et al.</i> , "A Model of Evolutionary Change in Proteins," <i>Atlas of Protein Sequence and Structure</i> , <u>5(3)</u> :345-352 (1978)
V	Diaz <i>et al.</i> , "Nomenclature of the Human Interferon Genes," <i>J. Interferon Cytokine Res.</i> , <u>16</u> :179-180 (1996)
W	Drittanti <i>et al.</i> , "Effects of 1,25-dihydroxyvitamin D-3 on phospholipid metabolism in chick myoblasts," <i>Biochim Biophys Acta</i> , <u>962(1)</u> :1-7 (1988)
X	Drittanti <i>et al.</i> , "Changes in muscle lipid metabolism induced in vitro by 1,25-dihydroxy-vitamin D-3," <i>Biochim Biophys Acta</i> , <u>918(1)</u> :83-92 (1987)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449

ATTY. DOCKET NO.
37851-922SERIAL NO.
10/658,834CONFIRM NO.
7681APPLICANT
GANTIER et al.CUSTOMER NO.
24961FILING DATE
September 8, 2003GROUP
1644

STATE OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Y	Drittanti <i>et al.</i> , "Involvement of the 3',5'-cyclic AMP pathway in the induction of calmodulin synthesis in myoblasts by 1,25(OH)2-vitamin D3," <i>Biochim Biophys Res Commun.</i> , <u>192(2)</u> :886-892 (1993)
Z	Drittanti <i>et al.</i> , "Modulation of DNA synthesis in cultured muscle cells by 1,25-dihydroxyvitamin D-3," <i>Biochim Biophys Acta.</i> , <u>1014(2)</u> :112-119 (1989)
AA	Drittanti <i>et al.</i> , "Stimulation of calmodulin synthesis in proliferating myoblasts by 1,25-dihydroxy-vitamin D3," <i>Mol Cell Endocrinol.</i> , <u>74(2)</u> :143-153 (1990)
AB	Drittanti <i>et al.</i> , "Optimised helper virus-free production of high-quality adeno-associated virus vectors," <i>J Gene Med.</i> , <u>3(1)</u> :59-71 (2001)
AC	Drittanti <i>et al.</i> , "Cystic fibrosis: gene therapy or preventive gene transfer?" <i>Gene Ther.</i> , <u>4(10)</u> :1001-1003 (1997)
AD	Drittanti <i>et al.</i> , "High throughput production, screening and analysis of adeno-associated viral vectors," <i>Gene Ther.</i> , <u>7(11)</u> :924-929 (2000)
AE	Du <i>et al.</i> , "Efficient transduction of human neurons with an adeno-associated virus vector," <i>Gene Ther</i> 3:254-261 (1996)
AF	Feng <i>et al.</i> , "Aligning Amino Acid Sequences: Comparison of Commonly Used Methods," <i>J. Mol. Evol.</i> , <u>21</u> :112-125 (1985)
AG	Fitch, "An Improved Method of Testing for Evolutionary Homology," <i>J. Mol. Evol.</i> , <u>16(1)</u> :9-16 (1966)
AH	Gibrat <i>et al.</i> , "Surprising similarities in structure comparison," <i>Current Opinion in Structural Biology</i> , <u>6</u> :377-385 (1995)
AI	Gonnet <i>et al.</i> , "Exhaustive Matching of the Entire Protein Sequence Database," <i>Science</i> , <u>256</u> :1433-1445 (1992)
AJ	Grantham, "Amino Acid Difference Formula to Help Explain Protein Evolution," <i>Science</i> , <u>185</u> :862-864 (1974)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449

ATTY. DOCKET NO.
37851-922SERIAL NO.
10/658,834CONFIRM NO.
7681APPLICANT
GANTIER et al.CUSTOMER NO.
24961FILING DATE
September 8, 2003GROUP
1644

If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AK	Grantier <i>et al.</i> , "The L392V mutation of presenilin 1 associated with autosomal dominant early-onset Alzheimer's disease alters the secondary structure of the hydrophilic loop," <i>Neuroreport</i> , <u>10(14)</u> :3071-3074 (1999)
AL	Grantier <i>et al.</i> , "The pathogenic L392V mutation of presenilin 1 decreases the affinity to glycogen synthase kinase-3 beta," <i>Neurosci Lett.</i> , <u>283(3)</u> :217-220 (2000)
AM	Guyon <i>et al.</i> , "Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction," <i>J Clin Invest.</i> , <u>94(1)</u> :16-24 (1994)
AN	Guyon <i>et al.</i> , "Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss," <i>J Clin Invest.</i> , <u>102(1)</u> :249-263 (1998)
AO	Henikoff <i>et al.</i> , "Amino acid substitution matrices from protein blocks," <i>Proc. Natl. Acad. Sci. USA</i> , <u>89</u> :10915-10919 (1992)
AP	Hibbert <i>et al.</i> , "Human Type 1 Interferons Differ Greatly in Their Effects on the Proliferation of Primary B Cells," <i>J. Interferon Cytokine Res.</i> , <u>19</u> :309-318 (1999)
AQ	Hoedemaekers <i>et al.</i> , "Differential susceptibility of young and old rat neuromuscular junctions to antibody-mediated AChR degradation in experimental autoimmune myasthenia gravis," <i>Ann N Y Acad Sci.</i> , <u>841</u> :550-554 (1998)
AR	Hoedemaekers <i>et al.</i> , "Role of target organ in determining susceptibility to experimental autoimmune myasthenia gravis," <i>J Neuroimmunol.</i> , <u>89(1-2)</u> :131-141 (1998)
AS	Holm <i>et al.</i> , "Mapping the Protein Universe," <i>Science</i> , <u>273</u> :595-602 (1996)
AT	IUPAC-IUB "Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids)," <i>Biochem.</i> , <u>11</u> :942-944 (1972)
AU	IUPAC-IUB "Commission on Biochemical Nomenclature A One-Letter Notation for Amino Acid Sequences Tentative Rules", <i>J. Biol. Chem.</i> , <u>243(13)</u> :3557-3559 (1968)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449

ATTY. DOCKET NO.
37851-922SERIAL NO.
10/658,834CONFIRM NO.
7681APPLICANT
GANTIER et al.CUSTOMER NO.
24961FILING DATE
September 8, 2003GROUP
1644

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the USPTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AV	Johnson <i>et al.</i> , "A Structural Basis for Sequence Comparisons. An Evaluation of Scoring Methodologies," <i>J. Mol. Biol.</i> , <u>233</u> :716-738 (1993)
AW	Jones <i>et al.</i> , "The rapid generation of mutation data matrices from protein sequences," <i>Comput. Appl. Biosci.</i> , <u>8</u> :275-282 (1992)
AX	Lu, G., "TOP: a new method for protein structure comparisons and similarity searches," <i>J. Appl. Cryst.</i> , <u>33</u> :176-189 (2000)
AY	Marrack <i>et al.</i> , "Type I Interferons Keep Activated T Cells Alive," <i>J. Exp. Med.</i> , <u>189</u> :521-530 (1999)
AZ	Masciovecchio <i>et al.</i> , "The interactivity between the CFTR gene and cystic fibrosis would be limited to the initial phase of the disease," <i>Genet Med.</i> , <u>2</u> (2):124-130 (2000)
BA	McLachlan, "Tests for Comparing Related Amino-acid Sequences. Cytochrome <i>c</i> and Cytochrome <i>c</i> ₅₅₁ ," <i>J. Mol. Biol.</i> , <u>61</u> :409-424 (1971)
BB	Miyata, "Two Types of Amino Acid Substitutions in Protein Evolution," <i>J. Mol. Evol.</i> , <u>12</u> :219-236 (1979)
BC	Morikawa <i>et al.</i> , "Recombinant interferon- α , - β and - γ enhance the proliferative response of human B cells," <i>J. Immunol.</i> , <u>139</u> :761-766 (1987)
BD	Moulian <i>et al.</i> , "Respective role of thymus and muscle in autoimmune myasthenia gravis," <i>Ann N Y Acad Sci.</i> , <u>841</u> :397-406 (1998)
BE	Murzin <i>et al.</i> , "SCOP: A Structural Classification of Proteins Database for the Investigation of Sequences and Structures," <i>J. Mol. Biol.</i> , <u>247</u> :536-540 (1995)
BF	Orengo <i>et al.</i> , "CATH - a hierarchic classification of protein domain structures," <i>Structure</i> , <u>5</u> (8):1093-1108 (1997)
BG	Pestka <i>et al.</i> , "Interferons and Their Actions," <i>Annu. Rev. Biochem.</i> , <u>56</u> :727-777 (1987)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 37851-922	SERIAL NO. 10/658,834	CONFIRM NO. 7681
	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 1644	

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BH	Piehler <i>et al.</i> , "New Structural and Functional Aspects of the Type I Interferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface," <i>J. Biol. Chem.</i> , <u>275</u> :40425-40433 (2000)
BI	Poea <i>et al.</i> , "Modulation of acetylcholine receptor expression in seronegative myasthenia gravis," <i>Ann Neurol.</i> , <u>48</u> (5):696-705 (2000)
BJ	Poëa <i>et al.</i> , "Expression of ciliary neurotrophic factor receptor in myasthenia gravis," <i>J Neuroimmunol.</i> , <u>120</u> (1-2):180-189 (2001)
BK	Rao, "New scoring matrix for amino acid residue exchanges based on residue characteristic physical parameters," <i>J. Pept. Protein Res.</i> , <u>29</u> :276-281 (1987)
BL	Raux <i>et al.</i> , "The -2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit," <i>Mol Psychiatry</i> , <u>7</u> (9):1006-1011 (2002)
BM	Raux <i>et al.</i> , "A novel presenilin 1 missense mutation (L153V) segregating with early-onset autosomal dominant Alzheimer's disease," <i>Human Mutat.</i> , Report #134, two pages (2000)
BN	Raux <i>et al.</i> , "Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation," <i>Neurol.</i> , <u>55</u> (10):1577-1578 (2000)
BO	Risler <i>et al.</i> , "Amino Acid Substitutions in Structurally Related Proteins A Pattern Recognition Approach," <i>J. Mol. Biol.</i> , <u>204</u> :1019-1029 (1988)
BP	Robert <i>et al.</i> , "Interferon Induces Proliferation In Leukemic And Normal B-Cell Subsets," <i>Hematol. Oncol.</i> , <u>4</u> :113-120 (1986)
BQ	Roisman <i>et al.</i> , "Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking," <i>Proc. Natl. Acad. Sci. USA</i> , <u>98</u> :13231-13236 (2001)
BR	Sali <i>et al.</i> , "Definition of General Topological Equivalence in Protein Structures," <i>J. Mol. Biol.</i> , <u>212</u> :403-428 (1990)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449



LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
37851-922

SERIAL NO.
10/658,834

CONFIRM NO.
7681

APPLICANT
GANTIER et al.

CUSTOMER NO.
24961

FILING DATE
September 8, 2003

GROUP
1644

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BS	Sanchez <i>et al.</i> , "Spastic paraplegia and primary adrenal insufficiency: a case of adrenomyeloneuropathy," <i>Medicina (B Aires)</i> , <u>48(3)</u> :290-296 (1988) (Summary in English)
BT	Scheel-Toeller <i>et al.</i> , "Inhibition of T cell apoptosis by IFN- β rapidly reverses nuclear translocation of protein kinase C- δ ," <i>Eur. J. Immunol.</i> , <u>29</u> :2603-2612 (1999)
BU	Shindyalov <i>et al.</i> , "Protein structure alignment by incremental combinatorial extension (CE) of the optimal path," <i>Protein Engineering</i> , <u>11(9)</u> :739-747 (1998)
BV	Smith <i>et al.</i> , "Single-step purification of polypeptides expressed in <i>Escherichia coli</i> as fusions with glutathione S-transferase," <i>Gene</i> , <u>67</u> :31-40 (1988)
BW	Stark <i>et al.</i> , "How cells Respond to Interferons," <i>Annu. Rev. Biochem.</i> , <u>67</u> :227-264 (1998)
BX	Wakkach <i>et al.</i> , "Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis," <i>J Immunol.</i> , <u>157(8)</u> :3752-3760 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**